Evidence map›Paper›PMID 35085762›Full record

ReviewJournal of cardiac failure2022

Economic Issues in Heart Failure in the United States.

Paul A Heidenreich, Gregg C Fonarow, Yekaterina Opsha, Alexander T Sandhu, Nancy K Sweitzer, Haider J Warraich, HFSA Scientific Statement Committee Members Chair

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of cardiac failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06921603 (Point-of-Care Ultrasound-Guided Diuresis for Acute Decompensated Heart Failure to Reduce 30-Day Readmissions and Acute Kidney Injury), which is not on this map. Cited by 89 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 5 pooled it
23.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06921603 narecruitingnot on this mapstarted 2025, after this paper: background citation

Point-of-Care Ultrasound-Guided Diuresis for Acute Decompensated Heart Failure to Reduce 30-Day Readmissions and Acute Kidney Injury

TypeinterventionalSponsorUniversity of PittsburghRan2025 to 2026Enrolled588ConditionsHeart Decompensation, Acute, Acute Kidney InjuriesArmsFurosemide (Standard Diuretic) Treatment, POCUS-Assessed Diuretic Management
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 5 syntheses or guidelines pooled it, 155 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Paul A HeidenreichDepartment of Medicine, Stanford University School of Medicine, Stanford, California; VA Palo Alto Health Care System, Palo Alto, California. Electronic address: heiden@stanford.edu.
Gregg C FonarowDivision of Cardiology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California.
Yekaterina OpshaErnest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey; Saint Barnabas Medical Center, Livingston, New Jersey.
Alexander T SandhuDepartment of Medicine, Stanford University School of Medicine, Stanford, California.
Nancy K SweitzerDivision of Cardiology, University of Arizona College of Medicine, Tucson, Arizona.
Haider J WarraichBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Medicine, Cardiology Section, VA Boston Healthcare System, Boston, Massachusetts.
HFSA Scientific Statement Committee Members Chair
Brigham and Women's Hospital · USRutgers, The State University of New Jersey · USStanford University · USUniversity of Arizona · USUniversity of California, Los Angeles · USVA Palo Alto Health Care System · US

Funding

The Effect of Value-based Payment on Heart Failure Quality of Care (Value-HF)K23HL151672 · NHLBI · STANFORD UNIVERSITY · PI SANDHU, ALEXANDER · 2020 to 2024
$854k
NHLBI NIH HHS K23 HL151672
6 · The paper itself

Abstract

The cost of heart failure care is high owing to the cost of hospitalization and chronic treatments. Heart failure treatments vary in their benefit and cost. The cost effectiveness of therapies can be determined by comparing the cost of treatment required to obtain a certain benefit, often defined as an increase in 1 year of life. This review was sponsored by the Heart Failure Society of America and describes the growing economic burden of heart failure for patients and the health care system in the United States. It also provides a summary of the cost effectiveness of drugs, devices, diagnostic tests, hospital care, and transitions of care for patients with heart failure. Many medications that are no longer under patent are inexpensive and highly cost-effective. These include angiotensin-converting enzyme inhibitors, beta-blockers and mineralocorticoid receptor antagonists. In contrast, more recently developed medications and devices, vary in cost effectiveness, and often have high out-of-pocket costs for patients.

Indexed as

Heart FailureAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCost-Benefit AnalysisHospitalizationHumansMineralocorticoid Receptor AntagonistsUnited StatesAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsMineralocorticoid Receptor Antagonists

Identifiers

PMID35085762
PMCPMC9031347
OpenAlexW4206901806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.